AB
CCCC icon

Amalgamated Bank’s C4 Therapeutics CCCC Stock Holding History

Amalgamated Bank’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,029
Closed -$3K – 3031
2025
Q1 		$3K Hold
2,029
– – ﹤0.01% 2772
2024
Q4 		$7K Hold
2,029
– – ﹤0.01% 2586
2024
Q3 		$12K Hold
2,029
– – ﹤0.01% 2350
2024
Q2 		$9K Buy
+2,029
New +$12.1K ﹤0.01% 2495
2023
Q2 		– Sell
-4,184
Closed -$13K – 3048
2023
Q1 		$13K Sell
4,184
-975
-19% -$5.74K ﹤0.01% 2763
2022
Q4 		$30K Hold
5,159
– – ﹤0.01% 2618
2022
Q3 		$45K Hold
5,159
– – ﹤0.01% 2506
2022
Q2 		$39K Sell
5,159
-1,131
-18% -$9.95K ﹤0.01% 2598
2022
Q1 		$153K Sell
6,290
-509
-7% -$12.4K ﹤0.01% 2039
2021
Q4 		$219K Sell
6,799
-65
-0.9% -$2.57K ﹤0.01% 1945
2021
Q3 		$307K Buy
6,864
+360
+6% +$15.4K ﹤0.01% 1834
2021
Q2 		$246K Buy
+6,504
New +$233K ﹤0.01% 1959

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Amalgamated Bank's CCCC Position: Q2 2025 in Review

Amalgamated Bank sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 2,029 shares — an estimated $3K sold.

Amalgamated Bank first reported a position in CCCC in Q2 2021 and held it in 12 quarters. The position peaked at $307K in Q3 2021. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • Amalgamated Bank reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Amalgamated Bank sold 2,029 C4 Therapeutics shares in Q2 2025, an estimated $3K.
  • Amalgamated Bank first reported a position in C4 Therapeutics in Q2 2021 and held it in 12 quarters.
  • Amalgamated Bank's C4 Therapeutics position peaked at $307K in Q3 2021.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on Amalgamated Bank's 13F filing for Q2 2025, filed 4 Aug 2025.